Eli Lilly and Co
Here are some of the companies saying weight loss drugs could impact their business
The impact of new weight loss treatments is being felt well beyond the health-care industry . Analysts used the ritual of quarterly earnings calls to probe companies on whether their businesses were being helped — or hampered by — the latest trend. Drugs that mimic gut hormones like glucagon-like peptide-1, or GLP-1, were first used […]
Read More
Weight loss drugs are priced substantially higher in the U.S. than in other countries, analysis says
In this photo illustration, a box of the diabetes drug Ozempic rests on a pharmacy counter on April 17, 2023 in Los Angeles, California. Mario Tama | Getty Images Blockbuster weight loss drugs are priced significantly higher in the U.S. than in other large, high-income countries, according to a new analysis released Thursday. The report […]
Read More
Here’s a rapid-fire update on all 36 stocks in the Club’s portfolio, including 2 recent buys
During the Investing Club’s August Monthly Meeting, Jim Cramer provided his latest thinking on all 36 names in his Charitable Trust. Source
Read More
These are the top 5 performing Club stocks from mid-July to our August Monthly Meeting
Since the CNBC Investing Club’s July Monthly Meeting, the stock market has seesawed up and then down on a slew of quarterly earnings results and inflation data. That’s left Wall Street struggling this month. Here’s a look at the best performers from the Club’s 36 holdings from the market close after the July 12 meeting […]
Read More
Activists ease up on Salesforce — plus, 10 other Club stocks traded by Wall Street pros
The extraordinary activist-investor interest in Salesforce (CRM) eased further in the second quarter, according to the latest regulatory filings from influential Wall Street pros. These big-name investors also made moves in nine other Club stocks during a strong three-month stretch that ended the best first half for the market in years. Starting with Salesforce, Dan […]
Read More
Eli Lilly gets a new price target after a big rally. Should I buy more shares?
Here’s our Club Mailbag email [email protected] — so you send your questions directly to Jim Cramer and his team of analysts. We can’t offer personal investing advice. We will only consider more general questions about the investment process or stocks in the portfolio or related industries. This week’s question: I’m learning so much from the […]
Read More
UBS says this stock is the ‘best story’ among U.S. large caps, sees more than 15% upside ahead
Eli Lilly has had a great run, but UBS expects about 16% further upside in the coming months as a steady stream of positive news propels the stock higher and revenue growth accelerates. Calling it the “best fundamental story” among U.S. large caps, UBS analyst Colin Bristow on Friday lifted his price target to $612 […]
Read More
Insurers face long road, high cost to cover obesity drugs after promising Wegovy heart health data
A selection of injector pens for the Saxenda weight loss drug are shown in this photo illustration in Chicago, Illinois, U.S., March 31, 2023. Jim Vondruska | Reuters Novo Nordisk‘s obesity drug Wegovy slashed the risk of serious heart problems by 20% in a large clinical trial – a landmark finding that could put more […]
Read More
We’re optimistic about this struggling entertainment stock despite an expected weak quarter
Every weekday the CNBC Investing Club with Jim Cramer holds a “Morning Meeting” livestream at 10:20 a.m. ET. Here’s a recap of Wednesday’s key moments. Back-to-back losses Still believe in Disney Eli Lilly keeps going 1. Back-to-back losses U.S. stocks on Wednesday were sinking for the second straight session ahead of this week’s key inflation […]
Read More